How chip technology opens the door to affordable personalized treatments.
Cancer treatment is going through a paradigm shift whereby patients’ own immune cells are modified to fight the disease. These patient-derived cell therapies are accelerating: the first FDA-approved therapies are reaching the market. They have the potential of saving millions of cancer patients, where conventional approaches failed.
To date, the cycle of retrieving the right immune cells, as well as the reengineering, upscaling and quality procedures for release and reinjection in the patient are still very cumbersome. Moreover, the process is not economically viable, difficult to scale and hard to standardize.
With a multitude of tools from different disciplines within the organization, imec can have a disruptive impact on the manufacturing process: from quality monitoring process to scalability, decentralization and efficacy. But we cannot do this alone.
That’s why we have the ambition to bring the ecosystem together to revolutionize the way cell therapies will be performed in the future.
In her talk from ITF Health, imec expert Katleen Verleysen fills you in on the possibilities that chip technology holds for cell therapy – including the hurdles we still need to take.
Katleen Verleysen has been active in the life sciences sector for over 20 years and has held various CEO/management positions and board seats: Serenex (NC, USA), ImmunExpress (WA, USA), Oxford Biodynamics (UK), Pronota (Belgium), PharmaFluidics (Belgium), DNameIT (Belgium). She successfully completed multiple rounds of funding for various companies. She is currently helping imec to finetune its healthcare strategy as well as enabling strategic partnerships. She is also board member of Immunexpress, a Seattle-based diagnostics company, representing the Janssen Family Office. Katleen holds a B.Sc. in Chemistry and a Ph.D. in Analytical Chemistry, from the University of Ghent. She was a postdoctoral fellow at the Medical Center of Duke University (NC, USA).